MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1182/bloodadvances.2025018139

Медицинская библиотека · Blood advances · 2026

No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapse.

Murdock H Moses, Kim Haesook T, Maurer Katie, Kelkar Amar, Shapiro Roman M, Gooptu Mahasweta, Romee Rizwan, Nageshwar Prashant K, Garrity Heather M, Shimony Shai, Luskin Marlise R, Winer Eric S, Vedula Rahul S, Stahl Maximillian, Chen Evan C, Volpe Virginia, Garcia Jacqueline S, Wadleigh Martha, DeAngelo Daniel J, Stone Richard M, Wu Catherine J, Cutler Corey S, Koreth John, Ritz Jerome, Antin Joseph H, Ho Vincent T, Nikiforow Sarah, Soiffer Robert J

СтатьяПеревод пока не подготовлен

Аннотация

Acute myeloid leukemia (AML) relapse after allogeneic hematopoietic stem cell transplant (HSCT) portends a dismal prognosis. One approach for reinvigorating a graft-versus-leukemia response is consolidation with donor lymphocyte infusions (DLI) or second HSCT (HSCT2). However, the role of DLI/HSCT2 in patients who achieve complete remission (CR) after salvage therapy is unclear. In this retrospective study, we evaluated the outcomes of 464 patients with post-HSCT AML relapse, focusing on those who achieved CR before consolidation with cellular therapy. In multivariable analysis (MVA), achieving CR after post-HSCT1 relapse was associated with improved overall survival (OS; hazard ratio [HR], 0.42; P< .0001). Of 133 patients (29%) who achieved CR after posttransplant AML relapse and before cellular therapy, 64 received DLI, 28 underwent HSCT2, and 41 received neither. Four-year outcomes from CR for the entire cohort (n = 133) were: OS 29%, relapse-free survival (RFS) 22%, cumulative incidence of relapse 58%, and nonrelapse mortality (NRM) 20%. In MVA, there was no association between receipt of DLI (HR, 0.87; P = .59) or HSCT2 (HR, 1.08; P = .83) and OS. Furthermore, we did not identify a benefit with DLI or HSCT2 with respect to RFS, relapse, or NRM. Patients with donor chimerism <90% at the time of CR had reduced 4-year OS (20% vs 32%; P = .03), as did measurable residual disease-positive patients (17% vs 62%; P = .024). Our results question the benefit of consolidation with DLI or HSCT2 in patients with AML who achieve CR, and we identify high-risk subgroups that should be the focus of future studies with larger cohorts.

Для цитирования: Murdock H Moses, Kim Haesook T, Maurer Katie, Kelkar Amar, Shapiro Roman M, Gooptu Mahasweta, Romee Rizwan, Nageshwar Prashant K, Garrity Heather M, Shimony Shai, Luskin Marlise R, Winer Eric S, Vedula Rahul S, Stahl Maximillian, Chen Evan C, Volpe Virginia, Garcia Jacqueline S, Wadleigh Martha, DeAngelo Daniel J, Stone Richard M, Wu Catherine J, Cutler Corey S, Koreth John, Ritz Jerome, Antin Joseph H, Ho Vincent T, Nikiforow Sarah, Soiffer Robert J. No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapse.. Blood advances. 2026. DOI: 10.1182/bloodadvances.2025018139.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.